The PDUFA date of February 12, 2027, is the primary catalyst. Traders should monitor for any FDA advisory committee meeting announcements and the planned Commercial Day in September 2026 for launch preparation details. The DRAGON II and PHOENIX trial interim data readouts could provide additional upside.
Price Chart
Executive Summary
Belite Bio reported Q2 2026 GAAP EPS of -$0.70, a miss vs consensus of -$0.78 (12.5% beat on a loss-per-share basis, but the GAAP loss widened to $28.4M from $16.3M YoY). The key catalyst is the FDA's acceptance of the NDA for tinlarebant with Priority Review and a PDUFA date of February 12, 2027, which is a pivotal milestone for the first potential approved treatment for Stargardt disease. The stock will move on the regulatory timeline and commercial preparation updates, not the quarterly financials, which are secondary for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- FDA accepted NDA for tinlarebant with Priority Review; PDUFA target action date February 12, 2027
- Q2 2026 GAAP net loss per share -$0.70 vs consensus -$0.78 (beat on loss basis)
- Cash and equivalents $279.9M plus $500.1M in U.S. treasury securities as of June 30, 2026
- Phase 3 DRAGON trial met primary endpoint; additional positive qAF data presented at ASRS
- DRAGON II trial fully enrolled (73 subjects); PHOENIX GA trial fully enrolled (530 subjects)
- R&D expenses $18.2M in Q2 2026 vs $11.0M YoY; SG&A $16.7M vs $6.5M YoY
- Net loss $28.4M in Q2 2026 vs $16.3M YoY; non-GAAP net loss $21.6M vs $8.7M YoY
Financial Impact
Pre-revenue; cash burn $28.4M net loss in Q2 2026; $780M in total cash and investments provides runway through potential approval and launch
Risk Factors
- FDA non-approval or Complete Response Letter (CRL) for tinlarebant
- Commercial execution risk if approved; competition from other STGD1 therapies
- Cash burn rate increasing as company scales commercial infrastructure
- Clinical trial failure in DRAGON II or PHOENIX could impair pipeline value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344190 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers